JP6794758B2 - 経口液体医薬組成物 - Google Patents
経口液体医薬組成物 Download PDFInfo
- Publication number
- JP6794758B2 JP6794758B2 JP2016200498A JP2016200498A JP6794758B2 JP 6794758 B2 JP6794758 B2 JP 6794758B2 JP 2016200498 A JP2016200498 A JP 2016200498A JP 2016200498 A JP2016200498 A JP 2016200498A JP 6794758 B2 JP6794758 B2 JP 6794758B2
- Authority
- JP
- Japan
- Prior art keywords
- oral liquid
- pharmaceutical composition
- liquid pharmaceutical
- acid
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007788 liquid Substances 0.000 title claims description 57
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 50
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 235000003599 food sweetener Nutrition 0.000 claims description 11
- 239000003765 sweetening agent Substances 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960005489 paracetamol Drugs 0.000 claims description 8
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 7
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 7
- 229960003291 chlorphenamine Drugs 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 239000004376 Sucralose Substances 0.000 claims description 6
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims description 6
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 6
- 229960002373 loxoprofen Drugs 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 5
- 229930091371 Fructose Natural products 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 229960001056 dimemorfan Drugs 0.000 claims description 5
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 4
- 229960004998 acesulfame potassium Drugs 0.000 claims description 4
- 239000000619 acesulfame-K Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000011007 phosphoric acid Nutrition 0.000 claims description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000011975 tartaric acid Substances 0.000 claims description 4
- 235000002906 tartaric acid Nutrition 0.000 claims description 4
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 3
- 229960002737 fructose Drugs 0.000 claims description 3
- 229960001031 glucose Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 244000228451 Stevia rebaudiana Species 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims 1
- 235000019640 taste Nutrition 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 5
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 4
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 4
- 229940041616 menthol Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WQOYJMWVNIGIQR-UHFFFAOYSA-N 3-(dithiophen-2-ylmethylidene)-1-methylpiperidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 WQOYJMWVNIGIQR-UHFFFAOYSA-N 0.000 description 3
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 description 3
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 3
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 description 3
- 241000544066 Stevia Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 guaifenecin Chemical compound 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- GJNMJOHYRWHJQB-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine;hydrochloride Chemical compound Cl.CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 GJNMJOHYRWHJQB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960002146 guaifenesin Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- YTKBWWKAVMSYHE-OALUTQOASA-N (3s)-3-[3-(3-hydroxy-4-methoxyphenyl)propylamino]-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](CC(O)=O)NCCCC=1C=C(O)C(OC)=CC=1)C1=CC=CC=C1 YTKBWWKAVMSYHE-OALUTQOASA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 239000004394 Advantame Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 108010093901 N-(N-(3-(3-hydroxy-4-methoxyphenyl) propyl)-alpha-aspartyl)-L-phenylalanine 1-methyl ester Proteins 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940086234 acetaminophen 300 mg Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000019453 advantame Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- ODJHDWLIOUGPPA-URVXVIKDSA-N dimemorfan phosphate Chemical compound OP(O)(O)=O.C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 ODJHDWLIOUGPPA-URVXVIKDSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940018415 meclizine hydrochloride Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
しかしながら、有効成分を水などに溶解すると、服用後の不快な後味が持続し、結果として服用コンプライアンスの低下を招来するという問題点がある。
しかし、これらの先行技術では、不快な後味を抑制するために配合したスクラロースの甘味の後残りや、メントールの薄荷様の香味が残り、後味のキレが悪いというデメリットがあり、所望するキレを確保しつつ、飲みやすい経口液体組成物の提供は困難であった。また、特に、メントールでは、メントール自身のもつ特有の異味・異臭が残るという課題があった。
(1)A)エチル−3−p−メンタン−3−カルボキサミドアセテート、及びB)アセトアミノフェン、ロキソプロフェンナトリウム、チペピジンクエン酸塩、クロルフェニラミンdl−マレイン酸塩、ジメモルファンリン酸塩、グアイフェネシン、デキストロメトルファン臭化水素酸塩、アンブロキソール塩酸塩、セチルピリジニウム塩化物及びメクリジン塩酸塩からなる群より選ばれる1種又は2種以上を含有することを特徴とする、経口液体医薬組成物、
(2)エチル−3−p−メンタン−3−カルボキサミドアセテートの含量が、経口液体医薬組成物中0.00001〜0.005W/V%であることを特徴とする、(1)に記載の経口液体医薬組成物、
(3)さらに、甘味剤及び/又は酸味剤を含有することを特徴とする、(1)又は(2)に記載の経口液体医薬組成物、
(4)甘味剤が、砂糖、ブドウ糖、果糖、ソルビトール、キシリトール、エリスリトール、アセスルファムカリウム、スクラロース及びステビア抽出物からなる群より選ばれる1種又は2種以上であることを特徴とする、(3)に記載の経口液体医薬組成物、
(5)酸味剤が、クエン酸、リンゴ酸、酒石酸、乳酸、アスコルビン酸及びリン酸からなる群より選ばれる1種又は2種以上であることを特徴とする、(3)又は(4)に記載の経口液体医薬組成物、
である。
さらに必要に応じて、抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、結合剤、滑沢剤、崩壊剤、コーティング剤、懸濁化剤、乳化剤、保存剤などの添加物を本発明の効果を損なわない範囲で適宜に配合することができる。
本発明の経口液体医薬組成物は、常法により調製することができ、その方法は特に限定されるものではない。内服液剤の場合、通常、各成分を秤量し、適量の精製水で溶解した後、pHを所望の酸性域に調整し、さらに精製水を加えて容量調整し、必要に応じてろ過、殺菌処理を施すことにより得られる。
アセトアミノフェン300mgと、エチル−3−p−メンタン−3−カルボキサミドアセテート(Penta Manufacturing社より購入、純度99.7%)を予め2W/V%となるよう99.5%エタノールに溶解したものを精製水に溶解し、さらに精製水を加えて全量を100mLとし、ガラス瓶に充填しキャップを施して経口液体医薬組成物を得た。
以下の実施例2〜30、及び比較例1〜57も実施例1と同様に調製した。なお、l−メントール、N−エチル−p−メンタン−3−カルボキサミド(別名:WS−3)、2−イソプロピル−N,2,3−トリメチルブタンアミド(別名:WS−23)についても、予め2W/V%となるよう99.5%エタノールに溶解したものを使用した。
表1〜9に示す経口液体医薬組成物を5〜15℃に冷却し、試験サンプルとした。得られた試験サンプルをカップに約10mL注ぎ、味のキレ、異味・異臭について専門パネル3名でブラインド評価した。表10に従い評価結果を数値化し、3名の評価結果の平均値を算出し、算出された平均値を表11の基準に従って示した。結果を表1〜9に示す。味のキレは「++」が最も良好な結果を表し、異味・異臭は「−−」が最も良好な結果を表す。
Claims (4)
- A)エチル−3−p−メンタン−3−カルボキサミドアセテート、及び
B)アセトアミノフェン、ロキソプロフェンナトリウム、チペピジンクエン酸塩、クロルフェニラミンdl-マレイン酸塩、ジメモルファンリン酸塩、グアイフェネシン、デキストロメトルファン臭化水素酸塩、アンブロキソール塩酸塩、セチルピリジニウム塩化物及びメクリジン塩酸塩からなる群より選ばれる1種又は2種以上を含有し、
A)エチル−3−p−メンタン−3−カルボキサミドアセテートの含量が、経口液体医薬組成物中0.00001〜0.005W/V%であることを特徴とする、経口液体医薬組成物。 - さらに、甘味剤及び/又は酸味剤を含有することを特徴とする、請求項1に記載の経口液体医薬組成物。
- 甘味剤が、砂糖、ブドウ糖、果糖、ソルビトール、キシリトール、エリスリトール、アセスルファムカリウム、スクラロース及びステビア抽出物からなる群より選ばれる1種又は2種以上であることを特徴とする、請求項2に記載の経口液体医薬組成物。
- 酸味剤が、クエン酸、リンゴ酸、酒石酸、乳酸、アスコルビン酸及びリン酸からなる群より選ばれる1種又は2種以上であることを特徴とする、請求項2又は3に記載の経口液体医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015207234 | 2015-10-21 | ||
JP2015207234 | 2015-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017078060A JP2017078060A (ja) | 2017-04-27 |
JP6794758B2 true JP6794758B2 (ja) | 2020-12-02 |
Family
ID=58665892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016200498A Active JP6794758B2 (ja) | 2015-10-21 | 2016-10-12 | 経口液体医薬組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6794758B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6844187B2 (ja) * | 2015-10-21 | 2021-03-17 | 大正製薬株式会社 | 経口液体組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5407665A (en) * | 1993-12-22 | 1995-04-18 | The Procter & Gamble Company | Ethanol substitutes |
US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
US6391886B1 (en) * | 2000-12-04 | 2002-05-21 | The Procter & Gamble Company | Oral compositions having improved consumer aesthetics |
WO2003011306A1 (en) * | 2001-07-31 | 2003-02-13 | Wyeth | Sucralose formulations to mask unpleasant tastes |
JP4373649B2 (ja) * | 2002-08-01 | 2009-11-25 | ロート製薬株式会社 | 経口用液剤 |
US20070178123A1 (en) * | 2006-01-27 | 2007-08-02 | Deborah Levenson | Flavor-enhancing compositions, method of manufacture, and methods of use |
US20100099766A1 (en) * | 2008-10-16 | 2010-04-22 | Novartis Ag | Topical NSAID compositions having sensate component |
US20110195042A1 (en) * | 2010-02-10 | 2011-08-11 | Thomas Edward Huetter | Compositions, Methods and Kits Useful for Treating a Respiratory Symptom |
CN104684412B (zh) * | 2012-10-05 | 2017-09-01 | 小川香料株式会社 | 粉末状清凉剂组合物 |
EP2932858A1 (de) * | 2014-04-16 | 2015-10-21 | Symrise AG | Homovanillinsäure-Ester, insbesondere zum Erzielen eines Wärme- und/oder Schärfeeindrucks |
JP6610001B2 (ja) * | 2015-05-28 | 2019-11-27 | ライオン株式会社 | 液体口腔用組成物 |
JP6844187B2 (ja) * | 2015-10-21 | 2021-03-17 | 大正製薬株式会社 | 経口液体組成物 |
-
2016
- 2016-10-12 JP JP2016200498A patent/JP6794758B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017078060A (ja) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11758933B2 (en) | High intensity sweeteners | |
JP5775597B2 (ja) | フランカルボン酸モメタゾン及び塩酸アゼラスチンを含む鼻内投与用医薬組成物 | |
US20110015227A1 (en) | Warming sensate composition | |
US9326935B2 (en) | Atomoxetine solution | |
JP5534806B2 (ja) | シトルリン含有飲料 | |
JP2003274896A (ja) | 苦味を呈するアミノ酸の苦味の低減剤とその用途 | |
EP3003384A1 (en) | Oral solution comprising atomoxetine hydrochloride | |
KR101326397B1 (ko) | 내복용 액제 | |
JP4190769B2 (ja) | 内服液組成物 | |
JP6794758B2 (ja) | 経口液体医薬組成物 | |
JP2002363105A (ja) | 不快な味のマスキング方法及び内服用液剤 | |
KR20170020859A (ko) | 단맛 수용체 안타고니스트 조성물 | |
JP4990515B2 (ja) | 味質の改善されたイソソルビド製剤 | |
JP6549428B2 (ja) | 経口組成物 | |
TW200911302A (en) | Pharmaceutical solutions | |
JP6410814B2 (ja) | フェキソフェナジンを含む経口投与用液体医薬組成物 | |
CN109640956B (zh) | 具有改善的味道和感官体验的药物 | |
JP5009707B2 (ja) | 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤 | |
JP4972311B2 (ja) | イソソルビドの苦味が軽減された経口製剤及びその製造方法 | |
JP2004292360A (ja) | イソソルビド含有水性組成物 | |
JPH09286723A (ja) | 改善された経口液剤 | |
JP2021505151A (ja) | 甘味料としてのトリプトファン誘導体 | |
JPH1036252A (ja) | ベラドンナ(総)アルカロイド配合内服液剤 | |
JP2012107060A (ja) | イソソルビドの苦味が軽減された経口製剤及びその製造方法 | |
JP2011231051A (ja) | ビタミンb1類含有経口ゼリー剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200728 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201026 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6794758 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |